Cigarette maker Philip Morris (PMI) clinched its 1.1 billion-pound takeover of asthma inhaler maker Vectura on Thursday, winning the support of the British company’s shareholders despite the concerns of health professionals. Vectura’s shareholders decided to take the 165 pence-per-share offer from PMI, with nearly 75 percent backing the deal. Buying the London-listed inhaler maker is part of Philip Morris’ long term plan to develop “smoke-free” products and switch to being a “broader healthcare and wellness” company. But it has angered health groups such as Asthma UK and the British Lung Foundation that have questioned whether a tobacco group should own a company that cures the very respiratory illnesses cigarettes cause. PMI Chief Executive Jacek Olczak has argued that acquiring Vectura is a critical part of his strategy to move the company “Beyond Nicotine”. He told the Telegraph last month that opponents of the deal were “not interested in progress” and …